Edition:
United Kingdom

People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

44.10USD
19 Jul 2019
Change (% chg)

$-0.64 (-1.43%)
Prev Close
$44.74
Open
$44.67
Day's High
$44.97
Day's Low
$43.96
Volume
125,695
Avg. Vol
191,757
52-wk High
$67.86
52-wk Low
$29.17

Aguiar, Eric 

Dr. Eric Aguiar, M.D., serves as Independent Director of the Company. Dr. Aguiar has served as a director of our Company since February 2017. Dr. Aguiar has been a partner at Aisling Capital since January 2016 and prior to that was a partner at Thomas, McNerney and Partners, a healthcare venture capital and growth equity fund, since 2007. Prior to joining that firm, he was a Managing Director of HealthCare Ventures, a healthcare-focused venture capital firm, from 2001 to 2007. Dr. Aguiar currently serves on the board of directors of Invitae Corporation (NYSE: NVTA), Eidos Therapeutics, Inc. (NASDAQ: EIDX) and BridgeBio, LLC. Dr. Aguiar is a member of the Board of Overseers of the Tufts School of Medicine and a member of the Council on Foreign Relations. Dr. Aguiar received his medical degree with honors from Harvard Medical School. He graduated with honors from Cornell University as a College Scholar. He was also a Luce Fellow and is a Chartered Financial Analyst. We believe that Dr. Aguiar’s medical and finance background and experience as an investor in life science companies qualifies him to serve as a member of our Board.

Basic Compensation

Total Annual Compensation, USD 621,360
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 41,250
Fiscal Year Total, USD 662,610

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Declan Doogan

706,360

Vlad Coric

7,854,000

James Engelhart

3,217,070

Kimberly Gentile

2,784,540

Charles Conway

2,792,860

Robert Berman

521,060
As Of  31 Dec 2018